NKNaoki Kohei

Naoki Kohei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoki Kohei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma

    by Naoki Kohei, Kyohei Sugiyama, Ichiro Chihara, Yusuke Muro, Masaaki Imamura, Yasunori Nishio, Koji Yoshimura

    Objectives: To evaluate the impact of relative dose intensity for gemcitabine–cisplatin chemotherapy in patients with metastatic urothelial carcinoma. Methods: We retrospectively reviewed the medical records of 18 patients with metastatic urothelial carcinoma, who received gemcitabine–cisplatin regimen as the first-line chemotherapy between 2009 and 2015. The doses of gemcitabine and cisplatin were reduced or the intervals between treatment cycles were prolonged according to the treatment efficacy and adverse events during the first and second cycles. The individually optimal relative dose intensity was set as the actual dose per the standard dose in the first and second cycles. From the third course onward, patients received the gemcitabine–cisplatin chemotherapy with the same relative dose intensity. Overall survival was compared with the groups according to the value of relative dose intensity. Results: The median age was 72.5 (range, 56–79) years and 15 men and 3 women were enrolled in the study. The median number of cycles of first-line gemcitabine–cisplatin chemotherapy was 8 (range, 2–17), and the median survival time from initiation of first-line chemotherapy was 20.1 (range, 3.5–32.8) months. The total median relative dose intensity of gemcitabine–cisplatin chemotherapy was 56.1%. The median survival time of 10 patients in the group with the relative dose intensity of less than 60% was significantly longer than that of 8 patients in the group with the relative dose intensity of more than 60% (19.2 and 11.0 months, respectively, p = 0.04). Conclusion: Individual low relative dose intensity management in the first-line gemcitabine–cisplatin chemotherapy may be an acceptable option for patients with metastatic urothelial carcinoma.


  • Open Access

    Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer

    by Yugo Sawada, Kazuya Omoto, Naoki Kohei, Kengo Sakaguchi, Masahiko Miura, Kazunari Tanabe

    Objectives: To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X‐ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics.Methods: Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100–300mm3, 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X‐ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally.Results: Combined treatment with sulfoquinovosylacylpropanediol plus X‐ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X‐ray irradiation.Conclusion: Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.


  • Open Access

    Clinical outcome of tubeless cutaneous ureterostomy by the Toyoda method

    by Akito Terai, Koji Yoshimura, Nobufumi Ueda, Noriaki Utsunomiya, Naoki Kohei, Yoichi Arai

    Aim: Cutaneous ureterostomy is the least invasive method of urinary diversion, but it carries a risk of stomal stenosis. We retrospectively examined the long‐term outcome of tubeless cutaneous ureterostomy by the Toyoda method. Methods: Since 1983, the Toyoda cutaneous ureterostomy has been performed in 97 patients (169 renal units) with a minimum follow up of 3 months. The ureteral patency rate was reviewed according to whether the stomal type was single (one ureter, one stoma) or double‐barrel (two ureters, one stoma). Results: After a median follow up of 23 months (range 3 to 169), a tubeless condition was achieved in 102 (82%) of 124 renal units associated with double‐barrel stoma and in 35 (78%) of 45 renal units associated with single stoma. Although mild to moderate hydronephrosis was observed in 19% of patients, serum creatinine levels did not change after a minimum of 12 months after surgery (median 35). Conclusions: A high ureteral patency rate was achieved with cutaneous ureterostomy using the Toyoda method. This procedure, especially double‐barrel stomal creation, is a reasonable alternative to other forms of urinary diversion in patients at high risk.